Back to Trials
NCT06323980NARecruiting

INHANCE Stemless Reverse Shoulder IDE

DePuy Orthopaedics

Start Date

3/4/2025

Completion Date

10/30/2028

Summary

2:1 Randomized, Controlled, Multi-Center, Prospective, Pre-Market Study of the INHANCE Stemless Reverse Cementless Total Shoulder.

Detailed Description

There is one primary effectiveness endpoint and there are three primary safety endpoints: 1. Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative 2. Primary safety endpoint(s): 1. No revision, removal, reoperation, supplemental fixation, or other intervention for any system component 2. No humeral or glenoid radiolucent line \>2 mm is present in 50% or more zones at 2 years 3. No conclusive evidence of migration and tilt (\>5mm migration and \>10° tilt) of the humeral or glenoid component at 2 years The study will be successful if the primary effectiveness endpoint non-inferiority analysis is successfully demonstrated, and no significant difference is seen on any of the 3 primary safety endpoints.

Eligibility Criteria

Age Range: 22 years to No maximum

Inclusion Criteria: 1. Individuals requiring reverse total shoulder replacement for a severely painful, disabling, arthritic joint (i.e. osteoarthritis, post-traumatic arthritis and rotator cuff arthropathy). 2. Individuals who are anatomically and structurally suited to receive the implants and have a functional deltoid muscle. 3. Individuals who are able to read and comprehend the informed patient consent document and are willing and able to provide informed patient consent for participation in the study and have authorized the transfer of their information to DePuy Synthes. 4. Individuals who are willing and able to return for follow-up as specified by the study protocol. 5. Individuals who are a minimum age of 22 years at the time of consent. 6. Individuals who are willing and able to complete the Patient Reported Outcome Measure questionnaires (PROMs) as specified by the study protocol. Exclusion Criteria: 1. BMI \> 40 kg/m2 2. Individuals have active, uncontrolled local infection or systemic infection. 3. Patients who have not reached skeletal maturity, regardless of age. 4. Either preoperatively or intraoperatively and per standard of care medical assessment, bone stock in the proximal humerus or glenoid fossa is determined to be inadequate for supporting the INHANCE humeral stemless components (NOTE: exclusion applies to both arms of the study, i.e., bone stock to be evaluated independent of randomized treatment assignment). 5. Intraoperatively and per treating physician's assessment of bone quality, bone is determined to be too soft or porous to support the implant or that is too hard or brittle to allow for proper bone preparation and fixation, i.e. osteoporosis or sclerotic bone, or tumor(s) of the supporting bone structure, where there could be considerable migration of the prosthesis and/or a chance of fracture of the humerus or glenoid. 6. Fractures of the proximal humerus that could compromise the fixation of the INHANCE reverse humeral stemless components. 7. Patients who have undergone previous treatment on the study shoulder that may compromise fixation of the INHANCE reverse humeral stemless component. 8. Revision of a failed hemi, total or reverse shoulder arthroplasty. 9. Patient is receiving, or is scheduled to receive, treatment that the Investigator considers could affect bone quality, such as chemotherapy or high dose corticosteroids. 10. Individuals who are bedridden per the Investigator's determination. 11. Individuals that have participated in a clinical investigation with an investigational product (drug or device) in the last three months. 12. Individuals currently involved in any personal injury litigation, medical-legal or worker's compensation claims. 13. Individuals, in the opinion of the Investigator, who are drug or alcohol abusers or have psychological disorders that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements. 14. Patients with a known medical condition that the Investigator believes would impact the study outcomes (including, but not limited to osteomyelitis, Paget's disease, neuropathies such as Charcot's disease, metastatic or neoplastic disorders). 15. Patient has a medical condition with less than 2 years life expectancy. 16. Patients who are known to be pregnant or breastfeeding. 17. Known polyethylene and/or metal sensitivity or allergy. 18. Contralateral side has been enrolled in the study or has received a total shoulder operation within the last 6 months 19. Otherwise determined by the investigator to be medically unsuitable for participation in this study 20. Patient is a member of a vulnerable population (i.e., incarcerated individuals - those incarcerated for at least one month and considered to be an inmate)

Interventions

DEVICE

Reverse Total Shoulder

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

ArthroplastyReplacementShoulder

Locations

Hoag Orthopedic Institute

Irvine, California 92618

United States

Cedars Sinai Medical Center

Los Angeles, California 90048

United States

Orthopedic Center of Palm Beach County

Atlantis, Florida 33462

United States

Hospital for Special Surgery

West Palm Beach, Florida 33401

United States

Boston Bone & Joint Institute BBJI Formerly BSSC

Waltham, Massachusetts 02451

United States

Trinity Health Grand Rapids

Grand Rapids, Michigan 49503

United States

Missouri Orthopaedic Institute (MOI)

Columbia, Missouri 65201

United States

OrthoCarolina Research Institute Charlotte

Charlotte, North Carolina 28207

United States

Duke Orthopaedics of Raleigh

Raleigh, North Carolina 27609

United States

Crystal Clinic Orthopaedic Center

Akron, Ohio 44333

United States

Lindner Research Center

Cincinnati, Ohio 45219

United States

The Cleveland Clinic Foundation

Cleveland, Ohio 44195

United States

Slocum Center for Orthopaedics and Sports Medicine

Eugene, Oregon 97401

United States

St. Luke's University Health Network

Bethlehem, Pennsylvania 18015

United States

Rothman Orthopaedics Institute

Philadelphia, Pennsylvania 19107

United States

MTBJ a division of Tennessee Orthaepedic Alliance

Columbia, Tennessee 38401

United States

TOSH- The Orthopedic Specialty Hospital

Murray, Utah 84107

United States

University of Utah

Salt Lake City, Utah 84108

United States

Mary Washington Orthopedics in affiliation with FOA

Fredericksburg, Virginia 22408

United States